Currently out of the existing stock ratings of Nathan Treybeck, 27 are a BUY (55.1%), 22 are a HOLD (44.9%).

Nathan Treybeck

Work Performance Price Targets & Ratings Chart

Analyst Nathan Treybeck, currently employed at WELLS FARGO, carries an average stock price target met ratio of 69.06% that have a potential upside of 15.1% achieved within 124 days.

Nathan Treybeck’s has documented 96 price targets and ratings displayed on 6 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on IRTC, iRhythm Technologies at 06-Oct-2026.

Wall Street Analyst Nathan Treybeck

Analyst best performing recommendations are on NVRO (NEVRO CORP).
The best stock recommendation documented was for NVRO (NEVRO CORP) at 8/7/2024. The price target of $5.5 was fulfilled within 1 day with a profit of $0.67 (13.87%) receiving and performance score of 138.72.

Average potential price target upside

IRTC iRhythm Technologies ITGR Integer Holdings Corp LMAT LeMaitre Vascular NVRO Nevro Corp PRCT Procept Biorobotics Corp RMD ResMed

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 13-Jan-2026

$150

$28.73 (23.69%)

$168

21 days ago
(06-Oct-2026)

6/11 (54.55%)

$42.8 (39.93%)

337

Buy Since 06-May-2022

$194

$72.73 (59.97%)

$192

22 days ago
(05-Oct-2026)

14/20 (70%)

$84.91 (77.83%)

330

Buy Since 07-Aug-2023

$168

$46.73 (38.53%)

$160

2 months 17 days ago
(10-Aug-2026)

13/20 (65%)

$43.22 (34.64%)

195

Buy Since 06-Apr-2026

$165

$43.73 (36.06%)

$150

2 months 20 days ago
(07-Aug-2026)

2/7 (28.57%)

$37.16 (29.07%)

34

Buy Since 21-Jan-2021

$185

$66.11 (55.61%)

$185

4 months 5 days ago
(22-Jun-2026)

10/15 (66.67%)

$80.31 (76.71%)

574

Show more analysts

Please expand the browser size to see the chart

Which stock is Nathan Treybeck most bullish on?

Potential upside of $28.73 has been obtained for IRTC (IRHYTHM TECHNOLOGIES)

Which stock is Nathan Treybeck most reserved on?

Potential downside of -$37.86 has been obtained for RMD (RESMED)

What Year was the first public recommendation made by Nathan Treybeck?

On 2022
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?